A Form 4 filed on November 2, 2026, discloses that John W. Frederick, a director of Tempest Therapeutics, Inc. (NASDAQ:TPST), was granted a stock option to purchase 25,000 shares of common stock on October 13, 2026, at an exercise price of $0.74 per share.

Key Highlights

  • Reporting Person: John W. Frederick, identified as a Director of Tempest Therapeutics, Inc.
  • Grant Date: The option was granted on October 13, 2026, with an expiration date of October 13, 2036.
  • Option Size: The award covers 25,000 shares of common stock, acquired at a price of $0.00 to the reporting person.
  • Exercise Price: The stock option carries an exercise price of $0.74 per share.
  • Vesting Schedule: According to the filing, one-third of the award vests on the first anniversary of the grant date, with the remainder vesting in equal monthly installments thereafter, subject to continued service.
  • Late Filing: The filing notes the transaction is being reported late "due to a delay in obtaining EDGAR codes from the Securities and Exchange Commission."

Tempest Therapeutics Director Receives Option Grant in October 2026

According to the Form 4 filed with the U.S. Securities and Exchange Commission, John W. Frederick, serving as a Director of Tempest Therapeutics, Inc. (NASDAQ:TPST), received a stock option grant on October 13, 2026. The derivative security, classified as a stock option (right to buy), covers 25,000 shares of the company's common stock and carries an exercise price of $0.74 per share. The transaction code is listed as "A" (acquired), and the price of the derivative security to the reporting person is listed as $0.00.

The filing specifies that the option expires on October 13, 2036, giving it a ten-year term from the grant date. Following the reported transaction, Frederick beneficially owns 25,000 derivative securities directly. No non-derivative securities were reported in Table I of the form.

The filing's footnote states that the shares subject to the option "will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service." The form was signed by John Frederick on November 2, 2026, and includes a remark that the transaction is being reported late due to a delay in obtaining EDGAR codes from the SEC.

What Was Disclosed

Tempest Therapeutics director John W. Frederick reported the acquisition of a stock option for 25,000 shares at an exercise price of $0.74, granted October 13, 2026, expiring October 13, 2036, with a three-year vesting schedule tied to continued service.